Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 45, Issue 3, 2014, Pages 212-216

  Rush, Ryan B ^a   Simunovic, Matthew P ^b,c   Aragon II, Antonio V ^a   Ysasaga, J Edward ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b SYDNEY EYE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL MACULAR THICKNESS; CLINICAL EXAMINATION; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PROCEDURES; MEDICAL RECORD REVIEW; MEDICARE; PRIORITY JOURNAL; RETINA MACULA EDEMA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREAT AND EXTEND PROCEDURE; TREATMENT DURATION; VISUAL ACUITY CHART; AGED; CLINICAL PROTOCOL; RETROSPECTIVE STUDY; TREAT AND EXTEND PROTOCOL; TREATMENT OUTCOME; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; ECONOMICS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINAL VEIN OCCLUSION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEALTH CARE COSTS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84901670238     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20140404-01     Document Type: Article

References (22)

1. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(4):513-518.
2. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984;98(3):271-282.
3. Aref AA, Scott IU. Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update. Adv Ther. 2011;28(1):28-39.
4. Campochiaro PA. Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica. 2012;227 Suppl 1:30-35.
5. Campochiaro PA, Hafiz G, Channa R, et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology. 2010;117(12):2387-2394 e2381-2385.
6. Brown DM, Campochiaro PA, Singh RP. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124-1133 e1121.
7. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594-1602.
8. Demir M, Oba E, Gulkilik G, Odabasi M, Ozdal E. Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results. Clin Ophthalmol. 2011;5:745-749.
9. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247(1):27-33.
10. Leitritz MA, Gelisken F, Ziemssen F, Szurman P, Bartz-Schmidt KU, Jaissle GB. Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. Br J Ophthalmol. 2013;97(2):215-219.
11. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina. 2009;29(4):511-515.
12. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115-1128.
13. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117(11):2134- 2140.
14. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina. 2011;31(1):26-30.
15. Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol. 2012;153(3):468-473.
16. Population by age and sex: 2010. In: Census Briefs Bureau USC, ed., 2011.
17. Yamaguchi Y, Otani T, Kishi S. Serous macular detachment in branch retinal vein occlusion. Retina. 2006; 26(9):1029-1033.
18. Bailey IL, Lovie JE. New design principles for visual acuity letter charts. Am J Optom Physiol Opt. 1976;53(11):740-745.
19. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802-9.
20. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):122-129.
21. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-908.
22. IVAN Study Investigators, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012l;119(7):1399-411.